Table 3.
Effect of tapering tocilizumab on achieving outcomes.
| CDAI-LDA | DAS28-remission | DAS28-deep remission | CDAI-remission | SDAI-remission | ACR/EULAR remission | |
|---|---|---|---|---|---|---|
| Unadjusted OR (95% CI) (vs. standard-dose group) |
0.98 (0.65 to 1.49) |
1.03 (0.71 to 1.49) |
0.76 (0.54 to 1.06) |
1.23 (0.75 to 2.00) |
0.92 (0.59 to 1.44) |
0.98 (0.65 to 1.48) |
| Adjusted OR (95% CI) (vs. standard-dose group) |
0.57 (0.33 to 0.99) |
0.87 (0.54 to 1.38) |
0.68 (0.46 to 0.99) |
0.94 (0.57 to 1.55) |
0.87 (0.54 to 1.38) |
0.76 (0.50 to 1.18) |
CDAI, clinical disease activity index; CI, confidence interval; DAS, disease activity score; LDA, low disease activity; OR, odds ratio; SDAI, simplified disease activity index.